SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-215623
Filing Date
2022-08-09
Accepted
2022-08-09 07:38:57
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d383613d8k.htm   iXBRL 8-K 27618
2 EX-10.1 d383613dex101.htm EX-10.1 268906
3 EX-99.1 d383613dex991.htm EX-99.1 96102
  Complete submission text file 0001193125-22-215623.txt   598564

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA itci-20220809.xsd EX-101.SCH 2901
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20220809_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20220809_pre.xml EX-101.PRE 10842
8 EXTRACTED XBRL INSTANCE DOCUMENT d383613d8k_htm.xml XML 3208
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 221146430
SIC: 2834 Pharmaceutical Preparations